Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.

Abstract

CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.

• Authors: Yining Zhao, Yumei Li, Xiaoqiong Wu, Li Li, Jiayu Liu, Yanlan Wang, Yue Liu, Qing Li, Zhong Wang
• Journal: Cancer biology & therapy (Cancer Biol Ther) Vol. 21 Issue 1 Pg. 72-80 ( 2020) ISSN: 1555-8576 [Electronic] United States
• PMID: 31564196 (Publication Type: Journal Article)

Chemical References

• Antibodies, Bispecific
• Antibodies, Monoclonal
• FCGR3A protein, human
• Peptide Library
• Receptors, IgG
• Single-Domain Antibodies

Topics

• Animals
• Antibodies, Bispecific (immunology, pharmacology)
• Antibodies, Monoclonal (immunology, pharmacology)
• Antibody-Dependent Cell Cytotoxicity
• Apoptosis
• Cell Proliferation
• Colonic Neoplasms (immunology, pathology, therapy)
• Female
• Humans
• Killer Cells, Natural (immunology)
• Mice
• Mice, Inbred NOD
• Mice, SCID
• Peptide Library
• Receptors, IgG (immunology)
• Single-Domain Antibodies (immunology, pharmacology)
• Tumor Cells, Cultured
• Xenograft Model Antitumor Assays